March 19, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Classification of US FDA Inspection at Unit V of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company – Reg.,

Ref: Our letter dated December 17, 2024

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The U.S. Food and Drug Administration (US FDA) had conducted an inspection at the Unit-V, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Pashamylaram Village, Patancheru Mandal, Sanga Reddy District, Telangana from December 09 to December 17, 2024.

The Unit has now received Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" ("VAI").

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.03.19 13:13:27 +05'30'

B. Adi Reddy
Company Secretary